Press Release

Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone - Seite 2

	Q4 2022	Change	Change at CER	2022	Change	Change at CER
IFRS net sales reported	€10,725m	+7.3%	+2.6%	€42,997m	+13.9%	+7.0%
IFRS net income reported	€1,460m	+29.1%	_	€6,720m	+8.0%	—
IFRS EPS reported	€1.16	+28.9%	_	€5.37	+8.0%	—
Free cash flow(3)	€2,546m	+0.2%	_	€8,483m	+4.8%	—
Business operating income	€2,724m	+20.7%	+15.0%	€13,040m	+21.7%	+13.3%
Business net income(1)	€2,141m	+23.8%	+17.6%	€10,341m	+25.9%	+17.0%
Business EPS(1)	€1.71	+23.9%	+17.4%	€8.26	+25.9%	+17.1%

Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q4 2022 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2022 business EPS was €8.26; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 9).

Attachment

• Press Release